We are live on ! Find out more
NTLA icon

Intellia Therapeutics

141 hedge funds and large institutions have $430M invested in Intellia Therapeutics in 2018 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 42 increasing their positions, 40 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $2.21M | Put options by funds: $1.43M

5.23% more ownership

Funds ownership: 67.37%72.6% (+5.2%)

5% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 40

10% less funds holding

Funds holding: 157141 (-16)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

42% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 36

48% less capital invested

Capital invested by funds: $833M → $430M (-$403M)

Holders
141
Holders Change
-16
Holders Change %
-10.19%
% of All Funds
3.14%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
21
Increased
42
Reduced
40
Closed
36
Calls
$2.21M
Puts
$1.43M
Net Calls
+$777K
Net Calls Change
+$4.25M
Name Holding Trade Value Shares
Change
Change in
Stake
State of Wisconsin Investment Board
51
State of Wisconsin Investment Board
Wisconsin
$470K +$11.2K +600 +2%
Wells Fargo
52
Wells Fargo
California
$462K -$537K -28,894 -46%
Royal Bank of Canada
53
Royal Bank of Canada
Ontario, Canada
$442K -$112K -6,031 -16%
Janney Montgomery Scott
54
Janney Montgomery Scott
Pennsylvania
$396K -$19 -1 -0%
CS
55
Credit Suisse
Switzerland
$363K +$27.4K +1,472 +6%
Citadel Advisors
56
Citadel Advisors
Florida
$354K +$14.7K +793 +3%
Bank of America
57
Bank of America
North Carolina
$333K -$248K -13,364 -35%
Susquehanna International Group
58
Susquehanna International Group
Pennsylvania
$309K +$201K +10,792 +91%
William Blair & Company
59
William Blair & Company
Illinois
$301K +$224K +12,060 +121%
AIG
60
American International Group
New York
$299K -$3.12K -168 -0.8%
CIM
61
CIM Investment Management
Pennsylvania
$297K
SC
62
Slow Capital
California
$289K +$172K +9,235 +77%
Two Sigma Advisers
63
Two Sigma Advisers
New York
$288K +$393K +21,117 New
Manulife (Manufacturers Life Insurance)
64
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$287K -$23.8K -1,282 -6%
ProShare Advisors
65
ProShare Advisors
Maryland
$249K -$64.5K -3,468 -16%
KJHP
66
K.J. Harrison & Partners
Ontario, Canada
$246K -$251K -13,500 -43%
SG
67
StoneX Group
New York
$246K -$33.5K -1,803 -9%
Walleye Trading
68
Walleye Trading
New York
$222K +$302K +16,246 New
BG
69
Bellevue Group
Switzerland
$216K -$11.2K -600 -4%
MIM
70
MetLife Investment Management
New Jersey
$215K
TAM
71
Tocqueville Asset Management
New York
$211K -$74.3K -4,000 -21%
Barclays
72
Barclays
United Kingdom
$209K -$18.9K -1,018 -6%
HighTower Advisors
73
HighTower Advisors
Illinois
$201K +$39.3K +2,115 +17%
DekaBank Deutsche Girozentrale
74
DekaBank Deutsche Girozentrale
Germany
$200K -$68.8K -3,700 -19%
VOYA Investment Management
75
VOYA Investment Management
Georgia
$196K +$28.2K +1,518 +12%

NTLA Hedge Fund Activity: Q4 2018 in Review

141 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q4 2018, worth a combined $430M — down 48% from $833M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of NTLA and 21 opened new positions — a net loss of 15 holders — while 40 trimmed existing stakes and 42 added.

The largest buyer was Ontario Teachers' Pension Plan Board, opening a new position worth an estimated $30.9M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $15.7M sold.

  • 141 institutional investors held Intellia Therapeutics (NTLA) as of Q4 2018, down from 157 in Q3 2018.
  • Funds reported $430M of Intellia Therapeutics stock for Q4 2018, down 48% quarter-over-quarter.
  • 21 funds opened new Intellia Therapeutics positions in Q4 2018 and 36 closed out, a net change of -15 holders.
  • The largest Intellia Therapeutics buyer in Q4 2018 was Ontario Teachers' Pension Plan Board, an estimated $30.9M added.
  • The largest Intellia Therapeutics seller in Q4 2018 was Farallon Capital Management, an estimated $15.7M sold.

Based on aggregated 13F filings for Q4 2018.